Literature DB >> 20140100

Antidepressants and suicide in adolescents and adults: a public health experiment with unintended consequences?

Jack Alan McCain.   

Abstract

Year:  2009        PMID： 20140100      PMCID： PMC2799109     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  37 in total

1.  Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs.

Authors:  Robert J Valuck; Anne M Libby; Heather D Orton; Elaine H Morrato; Richard Allen; Ross J Baldessarini
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

2.  Association of suicide and antidepressant prescription rates in Japan, 1999-2003.

Authors:  Atsuo Nakagawa; Michael F Grunebaum; Steven P Ellis; Maria A Oquendo; Haruo Kashima; Robert D Gibbons; J John Mann
Journal:  J Clin Psychiatry       Date:  2007-06       Impact factor: 4.384

3.  Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.

Authors:  Roy H Perlis; Charles M Beasley; James D Wines; Roy N Tamura; Cristina Cusin; Deborah Shear; Jay Amsterdam; Frederick Quitkin; Robert E Strong; Jerrold F Rosenbaum; Maurizio Fava
Journal:  Psychother Psychosom       Date:  2007       Impact factor: 17.659

4.  Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression?

Authors:  Michael Berk; Seetal Dodd
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

Review 5.  ACNP Task Force report on SSRIs and suicidal behavior in youth.

Authors:  J John Mann; Graham Emslie; Ross J Baldessarini; William Beardslee; Jan A Fawcett; Frederick K Goodwin; Andrew C Leon; Herbert Y Meltzer; Neal D Ryan; David Shaffer; Karen D Wagner
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

6.  Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.

Authors:  A Khan; H A Warner; W A Brown
Journal:  Arch Gen Psychiatry       Date:  2000-04

7.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

8.  Antidepressants and the risk of suicidal behaviors.

Authors:  Hershel Jick; James A Kaye; Susan S Jick
Journal:  JAMA       Date:  2004-07-21       Impact factor: 56.272

9.  Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.

Authors:  Hollis Reeves; Sachin Batra; Roberta S May; Rusheng Zhang; Daniel C Dahl; Xiaohua Li
Journal:  J Clin Psychiatry       Date:  2008-08       Impact factor: 4.384

10.  Persisting decline in depression treatment after FDA warnings.

Authors:  Anne M Libby; Heather D Orton; Robert J Valuck
Journal:  Arch Gen Psychiatry       Date:  2009-06
View more
  2 in total

1.  Selective Serotonin Reuptake Inhibitors (SSRIs) and Their Effect on Patient Aggression in Adult Patients in a State Psychiatric Facility: A Retrospective Analysis.

Authors:  Carolyn O'Donnell; Tammie Lee Demler; Eileen Trigoboff
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

2.  Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: A retrospective analysis.

Authors:  Felipe A Jain; Colm G Connolly; Victor I Reus; Dieter J Meyerhoff; Tony T Yang; Synthia H Mellon; Scott Mackin; Christina M Hough; Alexandra Morford; Owen M Wolkowitz
Journal:  Psychoneuroendocrinology       Date:  2019-07-26       Impact factor: 4.905
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.